Home / Intelligence / Case Studies / Cross-Functional Launch Strategy Alignment Workshop
Trinity organized a full day on-site workshop to bring together key cross functional client teams to align on a final launch strategy for their mNSCLC asset in Japan.
Geographic Scope: 
Client Situation:
The client wanted to build alignment on the launch pricing & market access assumptions for their asset in metastatic non-small cell lung cancer (mNSCLC) and metastatic colorectal cancer (mCRC) in Japan, including consideration of all forecasting assumptions and pricing and market access (P&MA) risks.
Trinity’s Solution:
Trinity conducted targeted secondary research to determine the existing mNSCLC and mCRC treatment paradigm, as well as oncology regulatory landscape in Japan.
Trinity then organized a full-day day workshop at the client’s local office in Japan to enable cross functional client teams to collaborate on forecasting assumptions and optimal launch strategies.
Deliverables
- Case studies of oncology analogues and recent pricing outcomes in JPN
- In-depth policy review of JPN’s new health technology assessment (HTA) process
- Final report with detailed summary of workshop outputs
- Final launch pricing and commercial strategy
Project Outcomes & Impact:
The workshop generated the opportunity for the client’s local team to deliver nuanced local expertise and strategic insights to the global team to ensure that the updated launch forecast model included realistic access assumptions.
Related Intelligence
Webinars
2023 NRDL Update: An Ongoing Voyage of Innovation and Accessibility
May 1, 2024 | 12:00 – 12:45 PM ET / 18:00 – 18:45 CET
An additional session will be offered on May 7th at 16:00-16:45 (UTC+8:00) – Asia/Shanghai How can manufacturers strategize for pricing and market access success amidst the evolving landscape of China’s NRDL? As China continues to be a key pharmaceutical market, understanding the latest National Reimbursement Drug List (NRDL) trends and policy evolvement is crucial for […]
Sign Up Now
Blog
Rise with the waves: Italy – AIFA restructuring and budget reforms – Stepping into a new (uncertain) future?
Executive Summary The Italian Medicines Agency (AIFA) underwent transformative changes on January 30, 2024, following a much-anticipated reorganization. AIFA’s restructuring has already faced challenges, with the recent resignation of the newly created Scientific and Economic Commission’s (CSE) chairman followed by the appointment of a new acting chairman, highlighting the need for a stable and collaborative […]
Read More
Webinars
Annual State of Global Market Access Webinar
Available On Demand
Trinity Life Sciences is pleased to release our highly anticipated white paper, the Annual State of Global Market Access. This year’s white paper focuses on six key global market access trends and provides payer perspectives on these trends. We explore the consequences of new therapeutic advances and policies aiming to control costs globally and the […]
Watch Now